匯豐:將港交所(0388.HK)目標價下調至348港元 維持持有評級
港交所(0388.HK)第3季純利增51.7%至33.5億港元,勝市場預期3%;首3季純利85.8億港元,按年上升16%,受三年以來最高現金成交額帶動。
匯豐證券報告指,將港交所目標價由350港元下調至348港元,維持持有評級;維持全年日均成交額(ADT)假設1250億港元不變,並略微下調衍生品及英國倫敦交易所相關日均預測。因此,將2020-2022年盈利預測削1-2%。儘管金融科技上市可能延遲,以及投資收益帶來的收益波動加劇,但該行認為港交所的新上市和新產品,長期的結構性增長有良好支持。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.